Inscopix, a provider of in vivo cellular imaging solutions, and SRI International have entered into a collaboration agreement on neuroscience imaging R&D program. Under the agreement, SRI's Center for Neuroscience and Metabolic ...
Tags: company cooperation, clinical research, clinical technology
Omeros has filed an investigational new drug application (IND) with the FDA for OMS824, the compound from its phosphodiesterase 10 (PDE10) program for schizophrenia and other cognitive disorders. OMS824 targets and inhibits an enzyme ...
Tags: new drug application, FDA, OMS824
Janssen Pharmaceuticals has settled its legal cases with 36 states and the District of Columbia regarding promotional and marketing practices for its atypical antipsychotic prescription medication Risperdal. The company will shell out ...
Tags: atypical antipsychotic prescription medication, rispedal
Wockhardt, a high-technology intensive pharmaceutical and biotechnology company, has gained tentative FDA approval for marketing Ziprasidone, a generic anti-psychotic drug Geodon. The FDA approved generic version of 20mg, 40mg, 60mg and ...
SureGene and PGXL Laboratories have joined forces to launch the SureGene Test for Antipsychotic and Antidepressant Response (STA2R), which is a pharmacogenetic test containing genetic markers for effectiveness of antipsychotic drug ...
Tags: STA2R, SureGene Test, pharmacogenetic test
The FDA has approved the stretched dose range for Sunovion Pharmaceuticals' Latuda for the treatment of patients with schizophrenia. After the review of the supplemental new drug application (sNDA), which was submitted in June 2011, ...
Tags: FDA, Schizophrenia, dose range for Latuda
Galenea and collaborator Kevin Spencer of the VA Boston Healthcare System and Harvard Medical School have won a five year $3m grant from the National Institute of Mental Health (NIMH). The grant is intended for the development of ...
Zogenix has commenced first IND clinical trial for Relday in patients with chronic, stable schizophrenia or schizoaffective disorder. Relday is based on a combination of its DosePro needle-free, subcutaneous drug delivery system with a ...
Tags: Clinical Trial, DosePro needle-free drug, pharmacokinetic
Mylan Pharmaceuticals has won final FDA approval for its abbreviated new drug application for Olanzapine tablets USP, 2.5mg, 5mg, 7.5mg, 10mg, 15mg, and 20mg. The company begins the shipment of the product, which is the generic equivalent ...
Tags: Generic Zyprexa Tablets, Mylan Pharmaceuticals, new drug
Catalent has started supplying its antipsychotic drug, Abilify, an orally disintegrating tablet (ODT) to Otsuka Pharmaceutical. Abilify ODT, which utilizes Catalent's Zydis fast dissolve drug delivery technology, is designed to improve ...
Tags: Catalent, Abilify Antipsychotic Drug, Otsuka Pharma, antipsychotic drug
XTL Biopharmaceuticals has acquired 4,620,356 shares of Proteologics from Teva Pharmaceutical for nearly NIS6.5m($1.6m). The company has purchased single share at an amount of NIS1.405($0.36). The acquired shares represent all the ...
Tags: XTL Biopharmaceuticals, shares, drugs, multiple myeloma, schizophrenia
Brainsway has started the multicenter clinical trial of its Deep TMS device, designed to treat various neurological and psychopathological disorders. Noninvasive Deep TMS device has also the potential to treat schizophrenia, obesity, ...
Tags: Brainsway, Deep TMS device, Parkinson's disease, Alzheimer's disease